Theravance Biopharma (TBPH) Receivables (2013 - 2019)

Theravance Biopharma (TBPH) has 7 years of Receivables data on file, last reported at $20.1 million in Q3 2019.

• Receivables for Q3 2019 came in at $20.1 million, up 189.81% year-over-year; the trailing twelve-month figure through Sep 2019 was $20.1 million (up 189.81% YoY), and the FY2018 annual result was $10.7 million, up 14.0% from the prior year.
• Receivables steadied at $20.1 million in Q3 2019 per TBPH's latest filing, from $20.1 million in the prior quarter.
• Over five years, Receivables peaked at $39.1 million in Q1 2016 and troughed at $4.8 million in Q1 2018.
• A 5-year average of $17.3 million and a median of $13.1 million in 2017 frame the typical range for Receivables.
• The sharpest annual moves came in 2015 and 2017: Receivables soared 674066.67% in 2015, then tumbled 81.96% in 2017.
• A 5-year view of Receivables shows it stood at $37.2 million in 2015, then slumped by 73.83% to $9.7 million in 2016, then slipped by 3.7% to $9.4 million in 2017, then climbed by 14.0% to $10.7 million in 2018, then jumped by 88.2% to $20.1 million in 2019.
• Business Quant data shows TBPH's Receivables at $20.1 million in Q3 2019, $20.1 million in Q2 2019, and $7.9 million in Q1 2019.